DOCSLIB.ORG

Fixed Drug Eruptions: a Case Report and Review of the Literature

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fixed Drug Eruptions: a Case Report and Review of the Literature CONTINUING MEDICAL EDUCATION Fixed Drug Eruptions: A Case Report and Review of the Literature Sarah B. Gendernalik, DO; Kenneth J. Galeckas, MD RELEASE DATE: October 2009 TERMINATION DATE: October 2010 The estimated time to complete this activity is 1 hour. GOAL To understand fixed drug eruption (FDE) to better manage patients with the condition LEARNING OBJECTIVES Upon completion of this activity, you will be able to: 1. Describe the clinical presentation of FDEs including nonpigmenting and generalized bullous FDEs. 2. Name the medications most commonly associated with FDEs. 3. Outline methods to determine the causative medication, including topical and oral provocation testing. INTENDED AUDIENCE This CME activity is designed for dermatologists and general practitioners. CME Test and Instructions on page 221. This article has been peer reviewed and approved by College of Medicine is accredited by the ACCME to provide Michael Fisher, MD, Professor of Medicine, Albert Einstein continuing medical education for physicians. College of Medicine. Review date: September 2009. Albert Einstein College of Medicine designates this edu- This activity has been planned and implemented in cational activity for a maximum of 1 AMA PRA Category 1 accordance with the Essential Areas and Policies of the Credit TM. Physicians should only claim credit commensurate Accreditation Council for Continuing Medical Education with the extent of their participation in the activity. through the joint sponsorship of Albert Einstein College of This activity has been planned and produced in accor- Medicine and Quadrant HealthCom, Inc. Albert Einstein dance with ACCME Essentials. Drs. Gendernalik and Galeckas report no conflict of interest. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis ® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Fixed drug eruptions (FDEs) have been described naproxen sodium in a 27-year-old woman. We since 1889 with continually evolving documenta- offer an inventory of common causes of FDEs as tion of implicated agents and clinical presenta- well as a discussion of the spectrum of clinical tions. We report a case of FDE as a reaction to presentations and differential diagnoses for this peculiar drug reaction. Dr. Gendernalik is a flight surgeon, Naval Air Station Whidbey Island, Oak Harbor, Washington. Dr. Galeckas is a staff dermatologist, Cutis. 2009;84:215-219. National Naval Medical Center, Bethesda, Maryland. The views expressed in this article are those of the authors and do not reflect the official policy or position of the US Department of ixed drug eruption (FDE) was first described the Navy, the US Department of Defense, or the US Government. 1 Correspondence: Kenneth J. Galeckas, MD, National Naval by Bourns in 1889 and has long been clini- Medical Center, Department of Dermatology, 8901 Rockville Pike, F cally described as a sudden eruption of round Bethesda, MD 20889-5600 ([email protected]). to oval, edematous, dusky red macules or patches on VOLUME 84, OCTOBER 2009 215 Fixed Drug Eruptions the skin and mucous membranes that leave residual ibuprofen was unavailable. At presentation she had a hyperpigmentation, most commonly as a reaction to hyperpigmented 5-cm patch with a 2- to 3-mm ery- orally ingested drugs or drug components.2 Recent thematous border that appeared 24 hours prior. After research has provided histologic and immunologic careful review of the patient’s medical history and insight into the natural course and pathophysiol- both prescription and over-the-counter medication ogy of the disease.3 With the advent of a multitude regimens as well as physical examination, the patient of new medications and preservatives within med- was diagnosed with an FDE in response to naproxen ications, physicians are seeing both typical and sodium. She was instructed to avoid this medication unusual presentations of FDEs often mimicking der- indefinitely and has not had any recurrences. Rechal- matologic entities such as erythema multiforme,4 lenge with ibuprofen proved uneventful and the Stevens-Johnson syndrome,5 toxic epidermal necroly- residual PIH completely faded without intervention. sis (TEN),5,6 cellulitis,7 paronychia,7 and bullous pem- phigoid.8,9 We aim to provide a comprehensive review Comment of FDEs and their implicated offenders. Fixed drug eruption is a unique form of drug allergy that characteristically occurs in the same site(s) with Case Report each administration of the inciting drug. After initial A 27-year-old woman presented to our dermatology use of the offending agent, a variable refractory period clinic with an erythematous patch over her right of weeks, months, or years may pass before the lesions popliteal fossa that had recurred over 2 years and was first appear on the skin of a sensitized individual.2 transient (Figure). She first noticed the lesion during With repeated exposure to the agent, either via oral the first trimester of pregnancy with her third child. or topical administration, acute lesions typically With the exception of intermittent use of pain reliev- develop within 30 minutes to 8 hours and present ers early on, she reported taking only prenatal vita- as single or multiple, round, sharply demarcated, mins and denied using over-the-counter medications. dusky red macules, patches, or plaques that may be Over the ensuing years, the lesion erupted quickly pruritic and edematous.10,11 Pruritus and burning multiple times without a prodrome and resolved in may be the only manifestations of reactivation in a 3 to 4 days with residual postinflammatory hyper- PIH lesion.12 Initial lesions typically are solitary, but pigmentation (PIH). When present, the lesion was with repeated ingestion of the offending drug, new erythematous and pruritic. She previously had used lesions may appear and original lesions may increase pimecrolimus cream 1% for atopic dermatitis without in size. Lesions may blister and erode, leaving residual clinical improvement. Her medical history included and persistent pigmentation changes, especially in atopic dermatitis and von Willebrand disease. She patients with darker skin phototypes (ie, Fitzpatrick reported taking ibuprofen for relief of menstrual skin types IV to VI). However, blister formation and symptoms with occasional use of naproxen sodium if erosion are not necessary to produce the hallmark PIH changes. Clinically, a PIH lesion may be the only remnant between attacks. A refractory phase may occur following an acute flare in which exposure to the offending drug will not exacerbate the lesion for weeks to months.13 The most common cause of FDE (of any type) is trimethoprim-sulfamethoxazole.14 Nonpigmenting FDE was first described in 1987 by Shelley and Shelley15 and is characterized by large, symmetric, well-circumscribed, tender, erythematous plaques, occasionally with large bullae over involved areas,3,15-20 that suddenly appear but fade over 2 to 3 weeks without the residual PIH characteristically seen in the more common FDEs.2 Diagnosis is con- firmed in these cases by appearance of the lesion at the exact location of prior eruptions. Pseudoephed- rine hydrochloride is the most common instigator of this particular eruption.21 It also has been seen follow- ing influenza vaccination and has been mistakenly 8,9 A 27-year-old woman with a recurrent hyperpigmented diagnosed initially as bullous pemphigoid. 5-cm patch with a 2- to 3-mm erythematous border over Generalized bullous FDEs, characterized by mul- the right popliteal fossa. tiple, sharply defined, deep red macules distributed 216 CUTIS® Additional Causes of Fixed Drug Eruptions2,3,7-9,14-20,23,24,27,28 Antibacterial and Psychoactive Agents Anti-inflammatory Agents Miscellaneous Antiviral Agents (continued) Barbituratesa Allopurinol Acyclovir Carbamazepine Ibuprofen Articaine Amoxicillin Chloral hydrate Indomethacin Atenolol Ampicillin Chlordiazepoxide hydrochloride Mefenamic acida Botulinum toxin Chlorhexidine gluconate Chlormezanone Metamizole sodium Cimetidineb Clarithromycin Citicoline Naproxen sodium Colchicine Clindamycin Codeine Nimesulide Contrast mediab Fluoroquinolones Lamotrigine Oxyphenbutazone Cyproterone acetate Foscarnet sodium Lormetazepam Phenacetin Docetaxel p-Aminosalicylic acid Ondansetron hydrochloride Phenazonea Melatonin Penicillin Opium alkaloids Phenylbutazonea Omeprazole Piroxicama Antiparasitic Agents Belladonna Oral contraceptives Papaverine Quinine sulfate Pamabrom Albendazole Oxazepam Tolfenamic acid Phenolphthalein Pyrantel pamoate Phenytoin Antihistamines Procarbazine Tinidazole Prochlorperazine maleate Tartrazine Cetirizine hydrochloride b Antifungal Agents Tropisetron Tetrahydrozoline Cyclizine Ticlopidine hydrochloride Anti-inflammatory Agents Azole antifungals Diphenhydramine hydrochloride Clioquinol Acetaminophena Hydroxyzine hydrochloride Griseofulvin Aspirin Loratadine VOLUME 84, OCTOBER 2009 Terbinafine hydrochloride Celecoxib Orphenadrine Fixed Drug Eruptions Diclofenac sodium Decongestants Diflunisal Dipyrone Amlexanox Ethenzamide Citiolone aKnown causes of generalized bullous fixed drug eruptions.23 b 3,8,9,15-20 217 Known causes of nonpigmenting fixed drug eruptions. Fixed Drug Eruptions bilaterally and often symmetrically2,3,22 may mimic Immunohistochemical studies demonstrate large num- erythema multiforme,4 Stevens-Johnson syndrome,5 bers of CD31CD81 T cells
Load more

Recommended publications
  • Generalized Edema Resulting from Mixed Intestinal Infection by Entamoebia Histolytica and E
    Case Report JOJ Case Stud Volume 12 Issue 2 -April 2021 Copyright © All rights are reserved by Ajite Adebukola DOI: 10.19080/JOJCS.2021.12.555833 Generalized Edema Resulting from Mixed Intestinal Infection by Entamoebia Histolytica and E. Coli in a Nigerian Female Adolescent: A Case Report Ajite Adebukola1,2*, Oluwayemi Oludare1,2 and Fatunla Odunayo2 1Department of Paediatrics, Ekiti State University, Nigeria 2Department of Paediatrics, Ekiti State University Teaching Hospital, Nigeria Submission: March 15, 2021; Published: April 08, 2021 *Corresponding author: Ajite Adebukola, Consultant Paediatrician, Department of Paediatrics, Ekiti State University, Ado Ekiti, Nigeria Abstract Amoebiasis, a clinical condition caused by Entamoeba histolytica does not usually present with generalized oedema known as anarsarca. We present a case of an adolescent female Nigerian who was admitted on account of chronic diarrhea and anarsarca in a tertiary hospital, Southwest Nigeria. There was no proteinuria. She however had cyst of E. histolytica and growth of E. coli in her stool; she also had E. coli isolated in her urine. She had hypoproteinaemia (35.2g/L) and hypoalbuminaemia (21.3g/L) as well as hypokalemia (2.97mmol/L). Symptoms resolved Entamoeba histolytica and Escherichia coli bacteria may be responsible for the worse clinical manifestations of Amoebiasis and biochemical parameters normalized following treatment with Nitrofurantoin, Tinidazole and Ciprofloxacin. A mixed infection of Keywords: Amoebiasis; Chronic diarrhea; Hypoproteinaemia; Anasarca Introduction Amoebiasis, caused by the protozoan Entamoeba histolytica of amenorrhoea. is an infection that frequently manifests clinically with symptoms recurrent generalized body swelling, and a seven-month history of abdominal pain, diarrhoea, dysentery and weight loss [1,2].
    [Show full text]
  • Autoimmune Associations of Alopecia Areata in Pediatric Population - a Study in Tertiary Care Centre
    IP Indian Journal of Clinical and Experimental Dermatology 2020;6(1):41–44 Content available at: iponlinejournal.com IP Indian Journal of Clinical and Experimental Dermatology Journal homepage: www.innovativepublication.com Original Research Article Autoimmune associations of alopecia areata in pediatric population - A study in tertiary care centre Sagar Nawani1, Teki Satyasri1,*, G. Narasimharao Netha1, G Rammohan1, Bhumesh Kumar1 1Dept. of Dermatology, Venereology & Leprosy, Gandhi Medical College, Secunderabad, Telangana, India ARTICLEINFO ABSTRACT Article history: Alopecia areata (AA) is second most common disease leading to non scarring alopecia . It occurs in Received 21-01-2020 many patterns and can occur on any hair bearing site of the body. Many factors like family history, Accepted 24-02-2020 autoimmune conditions and environment play a major role in its etio-pathogenesis. Histopathology shows Available online 29-04-2020 bulbar lymphocytes surrounding either terminal hair or vellus hair resembling ”swarm of bees” appearance depending on chronicity of alopecia areata. Alopecia areata in children is frequently seen. Pediatric AA has been associated with atopy, thyroid abnormalities and a positive family history. We have done a study to Keywords: find out if there is any association between alopecia areata and other auto immune diseases in children. This Alopecia areata study is an observational study conducted in 100 children with AA to determine any associated autoimmune Auto immunity conditions in them. SALT score helps to assess severity of alopecia areata. Severity of alopecia areata was Pediatric population assessed by SALT score-1. S1- less than 25% of hairloss, 2. S2- 25-49% of hairloss, 3. 3.S3- 50-74% of hairloss.
    [Show full text]
  • The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S
    ORIGINAL ARTICLE The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S. Antunes1, Amelia R. Aguilera1, Koji Tamada2 and Michael Croft1 Several inflammatory diseases including scleroderma and atopic dermatitis display dermal thickening, epidermal hypertrophy, or excessive accumulation of collagen. Factors that might promote these features are of interest for clinical therapy. We previously reported that LIGHT, a TNF superfamily molecule, mediated collagen deposition in the lungs in response to allergen. We therefore tested whether LIGHT might similarly promote collagen accumulation and features of skin fibrosis. Strikingly, injection of recombinant soluble LIGHT into naive mice, either subcutaneously or systemically, promoted collagen deposition in the skin and dermal and epidermal thickening. This replicated the activity of bleomycin, an antibiotic that has been previously used in models of scleroderma in mice. Moreover skin fibrosis induced by bleomycin was dependent on endogenous LIGHT activity. The action of LIGHT in vivo was mediated via both of its receptors, HVEM and LTβR, and was dependent on the innate cytokine TSLP and TGF-β. Furthermore, we found that HVEM and LTβR were expressed on human epidermal keratinocytes and that LIGHT could directly promote TSLP expression in these cells. We reveal an unappreciated activity of LIGHT on keratinocytes and suggest that LIGHT may be an important mediator of skin inflammation and fibrosis in diseases such as scleroderma
    [Show full text]
  • Seborrheic Dermatitis: an Overview ROBERT A
    Seborrheic Dermatitis: An Overview ROBERT A. SCHWARTZ, M.D., M.P.H., CHRISTOPHER A. JANUSZ, M.D., and CAMILA K. JANNIGER, M.D. University of Medicine and Dentistry at New Jersey-New Jersey Medical School, Newark, New Jersey Seborrheic dermatitis affects the scalp, central face, and anterior chest. In adolescents and adults, it often presents as scalp scaling (dandruff). Seborrheic dermatitis also may cause mild to marked erythema of the nasolabial fold, often with scaling. Stress can cause flare-ups. The scales are greasy, not dry, as commonly thought. An uncommon generalized form in infants may be linked to immunodeficiencies. Topical therapy primarily consists of antifungal agents and low-potency steroids. New topical calcineurin inhibitors (immunomodulators) sometimes are administered. (Am Fam Physician 2006;74:125-30. Copyright © 2006 American Academy of Family Physicians.) eborrheic dermatitis can affect patients levels, fungal infections, nutritional deficits, from infancy to old age.1-3 The con- neurogenic factors) are associated with the dition most commonly occurs in condition. The possible hormonal link may infants within the first three months explain why the condition appears in infancy, S of life and in adults at 30 to 60 years of age. In disappears spontaneously, then reappears adolescents and adults, it usually presents as more prominently after puberty. A more scalp scaling (dandruff) or as mild to marked causal link seems to exist between seborrheic erythema of the nasolabial fold during times dermatitis and the proliferation of Malassezia of stress or sleep deprivation. The latter type species (e.g., Malassezia furfur, Malassezia tends to affect men more often than women ovalis) found in normal dimorphic human and often is precipitated by emotional stress.
    [Show full text]
  • Immune Globulin Therapy
    Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 02/01/2013 Section: Prescription Drugs Place(s) of Service: Outpatient I. Description Intravenous immune globulin (IVIG) is a sterile, highly purified preparation of unmodified immunoglobulins, which are isolated from large pools of human plasma. IVIG is an infusion used to treat patients with inherited or acquired immune deficiencies. It provides passive immunity against infection by increasing a person’s antibody titer and antigen-antibody reaction potential. IVIG supplies a broad spectrum of IgG antibodies against bacterial, viral, parasitic, and mycoplasmal antigens. Subcutaneous immune globulin (Sub-q IG) is FDA approved for the treatment of patients with primary immune deficiency. It is injected under the skin using an infusion pump, which means patients can self-administer the product in a home setting. II. Criteria/Guidelines A. IVIG therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following indications: 1. Treatment of primary immunodeficiencies, including: a. Congenital agammaglobulinemia ( X-linked agammaglobulinemia) b. Hypogammaglobulinemia c. Common variable immunodeficiency d. X-linked immunodeficiency with hyperimmunoglobulin M e. Severe combined immunodeficiency f. Wiskott-Aldrich syndrome 2. Idiopathic thrombocytopenic purpura (ITP) Immune Globulin Therapy 2 3. Prevention of graft-versus-host disease in non-autologous bone marrow transplant patients age 20 or older in the first 100 days after transplantation 4. Kawasaki syndrome when used in conjunction with aspirin 5. Prevention of infection in: a. HIV-infected pediatric patients b. Bone marrow transplant patients age 20 or older in the first 100 days after transplantation c.
    [Show full text]
  • Pompholyx Factsheet Pompholyx Eczema (Also Known As Dyshidrotic Eczema/Dermatitis) Is a Type of Eczema That Usually Affects the Hands and Feet
    12 Pompholyx factsheet Pompholyx eczema (also known as dyshidrotic eczema/dermatitis) is a type of eczema that usually affects the hands and feet. In most cases, pompholyx eczema involves the development of intensely itchy, watery blisters, mostly affecting the sides of the fingers, the palms of the hands and soles of the feet. Some people have pompholyx eczema on their hands and/or feet with other types of eczema elsewhere on the body. This condition can occur at any age but is usually seen in adults under 40, and is more common in women. The skin is initially very itchy with a burning sensation of heat and prickling in the palms and/or soles. Then comes a sudden crop of small blisters (vesicles), which turn into bigger weepy blisters, which can become infected, causing redness, pain, swelling and pustules. There is often subsequent peeling as the skin dries out, and then the skin can become red and dry with painful cracks (skin fissures). Pompholyx eczema can also affect the nail folds and skin around the nails, causing swelling (paronychia). What causes it? A reaction could be the result of contact with potential irritants such as soap, detergents, solvents, acids/alkalis, The exact causes of pompholyx eczema are not known, chemicals and soil, causing irritant contact dermatitis. Or although it is thought that factors such as stress, there could be an allergic reaction to a substance that is sensitivity to metal compounds (such as nickel, cobalt or not commonly regarded as an irritant, such as rubber or chromate), heat and sweating can aggravate this nickel, causing allergic contact dermatitis.
    [Show full text]
  • Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002
    Department of Health & Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002 CHANGE REQUEST 2149 HEADER SECTION NUMBERS PAGES TO INSERT PAGES TO DELETE Table of Contents 2 1 45-30 - 45-31 2 2 NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2002 IMPLEMENTATION DATE: October 1, 2002 Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of Autoimmune Mucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Use J1563 to bill for IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid, and (5) Epidermolysis Bullosa Acquisita. This revision to the Coverage Issues Manual is a national coverage decision (NCD). The NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869(f)(1)(A)(i) of the Social Security Act.) These instructions should be implemented within your current operating budget. DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted. CMS-Pub.
    [Show full text]
  • Ehrlichiosis and Anaplasmosis Are Tick-Borne Diseases Caused by Obligate Anaplasmosis: Intracellular Bacteria in the Genera Ehrlichia and Anaplasma
    Ehrlichiosis and Importance Ehrlichiosis and anaplasmosis are tick-borne diseases caused by obligate Anaplasmosis: intracellular bacteria in the genera Ehrlichia and Anaplasma. These organisms are widespread in nature; the reservoir hosts include numerous wild animals, as well as Zoonotic Species some domesticated species. For many years, Ehrlichia and Anaplasma species have been known to cause illness in pets and livestock. The consequences of exposure vary Canine Monocytic Ehrlichiosis, from asymptomatic infections to severe, potentially fatal illness. Some organisms Canine Hemorrhagic Fever, have also been recognized as human pathogens since the 1980s and 1990s. Tropical Canine Pancytopenia, Etiology Tracker Dog Disease, Ehrlichiosis and anaplasmosis are caused by members of the genera Ehrlichia Canine Tick Typhus, and Anaplasma, respectively. Both genera contain small, pleomorphic, Gram negative, Nairobi Bleeding Disorder, obligate intracellular organisms, and belong to the family Anaplasmataceae, order Canine Granulocytic Ehrlichiosis, Rickettsiales. They are classified as α-proteobacteria. A number of Ehrlichia and Canine Granulocytic Anaplasmosis, Anaplasma species affect animals. A limited number of these organisms have also Equine Granulocytic Ehrlichiosis, been identified in people. Equine Granulocytic Anaplasmosis, Recent changes in taxonomy can make the nomenclature of the Anaplasmataceae Tick-borne Fever, and their diseases somewhat confusing. At one time, ehrlichiosis was a group of Pasture Fever, diseases caused by organisms that mostly replicated in membrane-bound cytoplasmic Human Monocytic Ehrlichiosis, vacuoles of leukocytes, and belonged to the genus Ehrlichia, tribe Ehrlichieae and Human Granulocytic Anaplasmosis, family Rickettsiaceae. The names of the diseases were often based on the host Human Granulocytic Ehrlichiosis, species, together with type of leukocyte most often infected.
    [Show full text]
  • ORIGINAL ARTICLE a Clinical and Histopathological Study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka
    ORIGINAL ARTICLE A Clinical and Histopathological study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka. Khaled A1, Banu SG 2, Kamal M 3, Manzoor J 4, Nasir TA 5 Introduction studies from other countries. Skin diseases manifested by lichenoid eruption, With this background, this present study was is common in our country. Patients usually undertaken to know the clinical and attend the skin disease clinic in advanced stage histopathological pattern of lichenoid eruption, of disease because of improper treatment due to age and sex distribution of the diseases and to difficulties in differentiation of myriads of well assess the clinical diagnostic accuracy by established diseases which present as lichenoid histopathology. eruption. When we call a clinical eruption lichenoid, we Materials and Method usually mean it resembles lichen planus1, the A total of 134 cases were included in this study prototype of this group of disease. The term and these cases were collected from lichenoid used clinically to describe a flat Bangabandhu Sheikh Mujib Medical University topped, shiny papular eruption resembling 2 (Jan 2003 to Feb 2005) and Apollo Hospitals lichen planus. Histopathologically these Dhaka (Oct 2006 to May 2008), both of these are diseases show lichenoid tissue reaction. The large tertiary care hospitals in Dhaka. Biopsy lichenoid tissue reaction is characterized by specimen from patients of all age group having epidermal basal cell damage that is intimately lichenoid eruption was included in this study. associated with massive infiltration of T cells in 3 Detailed clinical history including age, sex, upper dermis. distribution of lesions, presence of itching, The spectrum of clinical diseases related to exacerbating factors, drug history, family history lichenoid tissue reaction is wider and usually and any systemic manifestation were noted.
    [Show full text]
  • Atopic Dermatitis 101 for Adults
    TRIGGER TRACKER Atopic Dermatitis 101 for Adults WHAT IS ATOPIC DERMATITIS? IS THERE A CURE? Atopic dermatitis (AD) is the most common type There is no cure for of eczema. It often appears as a red, itchy rash or atopic dermatitis yet, dry, scaly patches on the skin. AD usually begins but there are treatments in infancy or childhood but can develop at any available and more are on the way. point in a person’s lifetime. It commonly shows up on the face, inside of the elbows or behind the WHAT ARE MY TREATMENT OPTIONS? knees, but it can appear anywhere on the body. It is important to have a regular schedule with AD care that includes bathing with a gentle IS IT CONTAGIOUS ? cleanser and moisturizing to lock water into the You can’t catch atopic dermatitis or spread it to skin and repair the skin barrier. Moisturized skin others. helps control flares by combating dryness and keeping out irritants and allergens. WHAT CAUSED IT? Depending on severity of symptoms and age, AD While the exact cause is unknown, researchers do treatments include lifestyle changes, over-the- know that people develop atopic dermatitis counter (OTC) and natural remedies, prescription because of a combination of genes and a trigger. topical medications, which are applied to the People with AD tend to have an over-reactive immune system that when triggered by skin; biologics, given by injection; something outside or inside the body, responds immunosuppressants, usually taken by mouth in by producing inflammation. It is this inflammation the form of a pill; and phototherapy, a form of that causes red, itchy and painful skin symptoms.
    [Show full text]
  • Effectiveness of Medium-Dose Ultraviolet A1 Phototherapy in Localized Scleroderma
    Pharmacology and therapeutics Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma Ozlem Su1, MD, Nahide Onsun1, MD, Hulya Kapran Onay2, MD, Yeliz Erdemoglu1, MD, Dilek Biyik Ozkaya1, MD, Filiz Cebeci1, MD, and Adnan Somay3, MD 1Department of Dermatology, Abstract Bezmialem Vakif University, Faculty of Background Recently, ultraviolet (UV) A1 phototherapy has been suggested as an effec- 2 Medicine, Neoson Imaging Center, tive treatment for localized scleroderma (LS); however, the optimal dose of UVA1 still has Radiology, and 3Department of not been determined. Pathology, Vakif Gureba Teaching and 2 Research Hospital, Istanbul, Turkey Objective We aimed to evaluate the therapeutic effectiveness of medium-dose (30 J/cm ) UVA1 phototherapy and to show that 13 MHz ultrasound is a valuable tool for assessing Correspondence the results of UVA1 phototherapy in LS. Ozlem Su, MD Methods Thirty-five patients with LS were treated with medium-dose (30 J/cm2) UVA1. Sıgırtmac Sok. No. 21 B blok d. 7 In total, 30–45 treatments and 900–1350 J/cm2 cumulative UVA1 doses were evaluated by Osmaniye Bakirkoy clinical scoring in all patients. In 14 patients, skin thickness was also determined by Istanbul 13 MHz ultrasound examination. Turkey Results In all patients, medium-dose UVA1 therapy softened sclerotic plaques, and E-mail: [email protected] marked clinical improvement was observed in 29 of 35 (82. 85%) patients. Ultrasound mea- surements showed that skin thickness was significantly reduced. No side effects were Conflicts of interest: None. observed during or after treatment. Conclusion Medium-dose UVA1 phototherapy is a highly effective, safe, and well-tolerated therapeutic modality for treatment of all types of LS.
    [Show full text]
  • How to Recognize a Suspected Cardiac Defect in the Neonate
    Neonatal Nursing Education Brief: How to Recognize a Suspected Cardiac Defect in the Neonate https://www.seattlechildrens.org/healthcare- professionals/education/continuing-medical-nursing-education/neonatal- nursing-education-briefs/ Cardiac defects are commonly seen and are the leading cause of death in the neonate. Prompt suspicion and recognition of congenital heart defects can improve outcomes. An ECHO is not needed to make a diagnosis. Cardiac defects, congenital heart defects, NICU, cardiac assessment How to Recognize a Suspected Cardiac Defect in the Neonate Purpose and Goal: CNEP # 2092 • Understand the signs of congenital heart defects in the neonate. • Learn to recognize and detect heart defects in the neonate. None of the planners, faculty or content specialists has any conflict of interest or will be presenting any off-label product use. This presentation has no commercial support or sponsorship, nor is it co-sponsored. Requirements for successful completion: • Successfully complete the post-test • Complete the evaluation form Date • December 2018 – December 2020 Learning Objectives • Describe the risk factors for congenital heart defects. • Describe the clinical features of suspected heart defects. • Identify 2 approaches for recognizing congenital heart defects. Introduction • Congenital heart defects may be seen at birth • They are the most common congenital defect • They are the leading cause of neonatal death • Many neonates present with symptoms at birth • Some may present after discharge • Early recognition of CHD
    [Show full text]